Prokidney to present react® at 4th annual ckd summit

Winston-salem, n.c., march 01, 2022 (globe newswire) -- prokidney lp (prokidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (ckd) and prevention of end-stage renal disease (esrd) and need for dialysis, today announced that joseph stavas, md, mph, senior vice president of clinical development, will present data on the company's lead product candiate, renal autologous cell therapy (react®) at the 4th annual ckd summit, being held march 1-3, 2022 in boston, ma.
PROK Ratings Summary
PROK Quant Ranking